Dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effect

Intraocular metastasis of cutaneous melanoma is extremely infrequent. This typically occurs in advanced metastatic disease and has a poor survival prognosis. The most frequent reported treatment is radiotherapy. BRAF inhibitors are new, orally administered and very effective drugs used for metastati...

Descripción completa

Detalles Bibliográficos
Autores: Fonollosa Calduch, Alejandro, Vargas Kelsh, Jose Gabriel, Garay Aramburu, Gonzaga, Saiz, Angel, Zabalza Estévez, Ignacio, Fernández, Ricardo
Tipo de recurso: artículo
Fecha de publicación:2017
País:España
Institución:Universidad del País Vasco
Repositorio:Addi. Archivo Digital para la Docencia y la Investigación
OAI Identifier:oai:addi.ehu.eus:10810/27389
Acceso en línea:http://hdl.handle.net/10810/27389
Access Level:acceso abierto
Palabra clave:dabrafenib
cutaneous melanoma
intraocular metastatic cutaneous melanoma
metastatic cutaneous melanoma
uveitis
vemurafenib
id ES_ab8712e3ea5d60b4e0d56fc18fbac5bc
oai_identifier_str oai:addi.ehu.eus:10810/27389
network_acronym_str ES
network_name_str España
repository_id_str
spelling Dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effectFonollosa Calduch, AlejandroVargas Kelsh, Jose GabrielGaray Aramburu, GonzagaSaiz, AngelZabalza Estévez, IgnacioFernández, Ricardodabrafenibcutaneous melanomaintraocular metastatic cutaneous melanomametastatic cutaneous melanomauveitisvemurafenibIntraocular metastasis of cutaneous melanoma is extremely infrequent. This typically occurs in advanced metastatic disease and has a poor survival prognosis. The most frequent reported treatment is radiotherapy. BRAF inhibitors are new, orally administered and very effective drugs used for metastatic cutaneous melanoma. Herein, we report a case of a 58-year-old patient with a recent diagnosis of cutaneous melanoma who consulted for floaters and presented vitreous opacities in both eyes. A diagnostic vitrectomy of his left eye was performed and pathologic analysis disclosed infiltrating melanoma cells in the vitreous. Treatment with dabrafenib (a type of BRAF inhibitor) achieved the regression of the intraocular metastasis in the right eye. Moreover, the patient presented a severe anterior uveitis due to dabrafenib, a well-known secondary effect of this drug.Springer201820182017info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10810/27389reponame:Addi. Archivo Digital para la Docencia y la Investigacióninstname:Universidad del País VascoIngléshttps://joii-journal.springeropen.com/articles/10.1186/s12348-017-0135-2info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/3.0/es/This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.Atribución 3.0 Españaoai:addi.ehu.eus:10810/273892026-06-18T09:23:17Z
dc.title.none.fl_str_mv Dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effect
title Dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effect
spellingShingle Dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effect
Fonollosa Calduch, Alejandro
dabrafenib
cutaneous melanoma
intraocular metastatic cutaneous melanoma
metastatic cutaneous melanoma
uveitis
vemurafenib
title_short Dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effect
title_full Dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effect
title_fullStr Dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effect
title_full_unstemmed Dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effect
title_sort Dabrafenib for cutaneous melanoma infiltrating the vitreous: regression of metastasis and occurrence of uveitis as a secondary effect
dc.creator.none.fl_str_mv Fonollosa Calduch, Alejandro
Vargas Kelsh, Jose Gabriel
Garay Aramburu, Gonzaga
Saiz, Angel
Zabalza Estévez, Ignacio
Fernández, Ricardo
author Fonollosa Calduch, Alejandro
author_facet Fonollosa Calduch, Alejandro
Vargas Kelsh, Jose Gabriel
Garay Aramburu, Gonzaga
Saiz, Angel
Zabalza Estévez, Ignacio
Fernández, Ricardo
author_role author
author2 Vargas Kelsh, Jose Gabriel
Garay Aramburu, Gonzaga
Saiz, Angel
Zabalza Estévez, Ignacio
Fernández, Ricardo
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv dabrafenib
cutaneous melanoma
intraocular metastatic cutaneous melanoma
metastatic cutaneous melanoma
uveitis
vemurafenib
topic dabrafenib
cutaneous melanoma
intraocular metastatic cutaneous melanoma
metastatic cutaneous melanoma
uveitis
vemurafenib
description Intraocular metastasis of cutaneous melanoma is extremely infrequent. This typically occurs in advanced metastatic disease and has a poor survival prognosis. The most frequent reported treatment is radiotherapy. BRAF inhibitors are new, orally administered and very effective drugs used for metastatic cutaneous melanoma. Herein, we report a case of a 58-year-old patient with a recent diagnosis of cutaneous melanoma who consulted for floaters and presented vitreous opacities in both eyes. A diagnostic vitrectomy of his left eye was performed and pathologic analysis disclosed infiltrating melanoma cells in the vitreous. Treatment with dabrafenib (a type of BRAF inhibitor) achieved the regression of the intraocular metastasis in the right eye. Moreover, the patient presented a severe anterior uveitis due to dabrafenib, a well-known secondary effect of this drug.
publishDate 2017
dc.date.none.fl_str_mv 2017
2018
2018
dc.type.none.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/10810/27389
url http://hdl.handle.net/10810/27389
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv https://joii-journal.springeropen.com/articles/10.1186/s12348-017-0135-2
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/3.0/es/
Atribución 3.0 España
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/3.0/es/
Atribución 3.0 España
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:Addi. Archivo Digital para la Docencia y la Investigación
instname:Universidad del País Vasco
instname_str Universidad del País Vasco
reponame_str Addi. Archivo Digital para la Docencia y la Investigación
collection Addi. Archivo Digital para la Docencia y la Investigación
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869416277095743488
score 15.301603

Similares en LA Referencia